Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape

Table 1 Clinical trials of oncolytic virus for hepatocellular carcinoma

Trial number	Virus	Disease	Status	Interventions	Trail phase	Study start
NCT00844623	TK99UN	HCC	Completed	Alone	I	2002
NCT00003147	Ad5CMV-p53 gene	Liver cancer	Completed	Alone	I	1998
NCT02509169	rAd-p53	HCC	Unknown status	Alone	II	2014
NCT00300521	ADV-TK	Advanced HCC	Completed	Alone	II	2000
NCT02418988	rAd-p53	Advanced HCC	Unknown status	TACE	II	2014
NCT01869088	H101	HCC	Unknown status	TACE	III	2013
NCT03790059	H101	HCC	Unknown status	RFA	Not applicable	2016
NCT03313596	ADV-Tk	Advanced HCC	Unknown status	LT	III	2013
NCT05113290	H101	HCC	Unknown status	Sorafenib	IV	2021
NCT00629759	JX-594	Primary hepatocellular carcinoma	Completed	Alone	I	2006
NCT00554372	JX-594	Primary hepatocellular carcinoma	Completed	Alone	II	2008
NCT02562755	JX-594	HCC	Completed	Sorafenib	III	2015
NCT01387555	JX-594	HCC failed sorafenib treatment	Completed	Alone	II	2008
NCT02509507	T-Vec	HCC et al	Active, not recruiting	Pembrolizumab	I/II	2016
NCT04313868	GEN2	Metastatic HCC	Recruiting	Alone	I	2014
NCT05223816	VG161	HCC et al	Recruiting	Nivolumab	II	2023
NCT01628640	VSV (IFN-β)	HCC	Active, not recruiting	Alone	I	2012
NCT04665362	M1 virus	Advanced/metastatic hepatocellular carcinoma	Unknown status	Anti PD-1 antibody and apatinib	I	2021

VSV: Vesicular stomatitis virus; IFN-β: Interferon-beta; HCC: Hepatocellular carcinoma.